| Species |
Human |
| Protein Construction |
| His |
FGF-7/KGF (Cys32-Thr194)
Accession # P21781-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 0.1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized FGF-7/KGF, His, Human at 5μg/ml (100μl/well) on the plate can bind Human FGFR2 beta (IIIb), hFc Tag. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
20.1 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 20.1 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 50mM Tris, 250mM NaCl (pH 7.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The expression patterns of mRNAs encoding Fibroblast Growth Factor-7 (FGF-7) and its high affinity receptor suggested that FGF-7 signaling may play a role in regulating ureteric bud growth.t Results of these studies demonstrate that the developing ureteric bud and mature collecting system of FGF-7-null kidneys is markedly smaller than wild type. FGF-7 levels modulate the extent of ureteric bud growth during development and the number of nephrons that eventually form in the kidney. |
| Synonyms |
FGF-7; HBGF-7; KGF; FGF7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
